MCL plans major investment in multiple sclerosis research program
Date: 2018-02-26   Author: Saipriya Iyer  Category: #news

MCL plans major investment in multiple sclerosis research program

Medical Cannabis Limited (MCL), a division of Queensland Bauxite Limited, has reportedly decided to fund a research program dealing with the deployment of the medical cannabis therapy for multiple sclerosis. It has been speculated that this is the first such initiative taken by MCL to fund any research program on the multiple sclerosis disorder.

As per the agreement between Technion Research & Development Foundation and Medical Cannabis Research Group Private Limited, MCL will promote research & development activities associated with the use of the medical marijuana in treating multiple sclerosis symptoms and stopping the growth of autoimmune diseases. The research is expected to be based on the recognition of synergistic relations between the human genome and the cannabis shrub.

Some of the key executives at the Technion Research & Development Foundation have stated that the main goal of the research program is to recognize particular cannabis compounds, which can find applications in the clinical tests for treating patients with multiple sclerosis. In return for the funding of the research program, which will be carried out under the auspices of Prof. Meiri, MCL will be granted exclusive licensing rights for any product discovered during the research & development activities.

As per the terms & conditions of the deal between the two institutions, Medical Cannabis Research Group (MCRG) will make capital investments worth USD 3 million in the project over the span of three years. In return, MCRG will receive exclusive rights to multiple sclerosis or autoimmune disorder therapies developed via the research project.

Myriad research activities on how medical marijuana can help in treating multiple sclerosis syndrome or autoimmune ailment are now being carried out in several regions across the globe. Experts claim that as on today, the healthcare industry is focusing more on finding cures for incontinence, spasticity, and pain. They also have reason to believe that this strategic move to fund the research on treating multiple sclerosis will promote a further slew of R&D activities to find cures for acute & chronic autoimmune disorders such as multiple sclerosis.



About Author


Saipriya Iyer

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

More from Saipriya


Post Recommendents

Increased Demand For Organic Food To Expand Biopesticides Market Size
Author: Rahul Varpe

Large number of crops are affected every year due to pests and insects attack. Increasing demand for organic pest control from farming sector will fuel the adoption rate of bioinsecticides in the forthcoming years. Bio...


Growing Demand For Well-Maintained Vehicles To Impel Automotive Coatings Market Outlook
Author: Rahul Varpe

This shift in preference towards refurbished cars is likely to add great impetus to the automotive coatings market outlook. Rising inclination of customers towards customization and overall maintenance of their refurbi...


Vitamin Ingredients market Growth & Regional Forecast To 2026
Author: Rahul Varpe

Market Overview: –

 

The global Vitamin Ingredients market was valued at USD 2 Billion in 2017 and is projected to touch USD 7 Billion by 2024, developing at a CAGR of 5.9 % from 2019 to 2024. Decresearch declares th...